Community-acquired pneumonia

Thomas M File, Thomas M File

Abstract

This seminar reviews important features and management issues of community-acquired pneumonia (CAP) that are especially relevant to immunocompetent adults in light of new information about cause, clinical course, diagnostic testing, treatment, and prevention. Streptococcus pneumoniae remains the most important pathogen; however, emerging resistance of this organism to antimicrobial agents has affected empirical treatment of CAP. Atypical pathogens have been quite commonly identified in several prospective studies. The clinical significance of these pathogens (with the exception of Legionella spp) is not clear, partly because of the lack of rapid, standardised tests. Diagnostic evaluation of CAP is important for appropriate assessment of severity of illness and for establishment of the causative agent in the disease. Until better rapid diagnostic methods are developed, most patients will be treated empirically. Antimicrobials continue to be the mainstay of treatment, and decisions about specific agents are guided by several considerations that include spectrum of activity, and pharmacokinetic and pharmacodynamic principles. Several factors have been shown to be associated with a beneficial clinical outcome in patients with CAP. These factors include administration of antimicrobials in a timely manner, choice of antibiotic therapy, and the use of a critical pneumonia pathway. The appropriate use of vaccines against pneumococcal disease and influenza should be encouraged. Several guidelines for management of CAP have recently been published, the recommendations of which are reviewed.

References

    1. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet. 1998;352:1295–1302.
    1. Working Groups of the South African Pulmonology Society and the Antibiotic Study Group of South Africa Management of communityacquired pneumonia in adults. S Afr Med J. 1996;86:1152–1163.
    1. Dorca J, Bello S, Blanquer J. Diagnostico y tratamiento de la neumonia adquirida en la comunidad. Arch Bronconeumol. 1997;33:240–246.
    1. Task Force on CAP, Philippine Practice Guidelines Group in Infectious Diseases: Community-acquired pneumonia: clinical practice guideline. PPGG-ID Philippine Society for Microbiology and Infectious Diseases. 1998; 1(2).
    1. Heffelfinger JD, Dowell SF, Jorgensen JH. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399–1408.
    1. Bartlett JG, Dowell SF, Mandell LA, File TM, Jr, Musher DM, Fine MJ. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347–382.
    1. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405–1433.
    1. Mandell LA, Marrie TJ, Grossman RE. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the canadian infectious diseases society and the canadian thoracic society. Clin Infect Dis. 2000;31:383–421.
    1. Niederman MS, Mandell LA, Anzueto A. Guidelines for the management of adults with community-acquired pneumonia. (American Thoracic Society) Am J Respir Crit Care Med. 2001;163:1730–1754.
    1. Vogel F, Paul Ehrlich Society for Chemotherapy and the German Respiratory Association Rational treatment of bacterial respiratory tract infections. Chemother J. 2000;9:3–23.
    1. Anonymous . Therapeutic Guidelines: antibiotic (version 11) Therapeutic Guidelines Ltd; North Melbourne: 2000.
    1. Matsushima T, Kohno S, Saito A, Japanese Respiratory Society Community-Acquired Pneumonia Treatment Guideline Creation Committee, editors. Diagnostic and treatment guideline for community-acquired pneumonia. Japanese Respiratory Society; Tokyo: 2000. General Managing Director Ando Massayuki; [Also reviewed in Yangihar K, Kohno S, Matsushima T. Japanese guidelines for the management of community-acquired pneumonia. Intern J Antimicrob Agents 2001; 18: S45–48.]
    1. Grupo de Trabajo de la Asociacion Latinoamericana del Torax (ALAT) Recomendaciones ALAT sobre la neumonia adquirida en la communidad. Arch Bronconeumol. 2001;37:340–348.
    1. Guidelines of Infectious Diseases French Society What should the initial antibiotherapy for acute community-acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used? Med Mal Infect. 2001;31:357–363.
    1. British Thoracic Society Guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001;56(suppl 4):1–64. iv.
    1. Fine MJ, Smith MA, Carson CA. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA. 1996;275:134–141.
    1. Nuorti JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF. Cigarette smoking and invasive pneumococcal disease. N Eng J Med. 2000;342:681–689.
    1. Marston BJ, Plouffe JF, File TM, Jr, the CBPIS Study Group Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med. 1997;157:1709–1718.
    1. Jokinen C, Heiskanen L, Juvonen H. Microbial aetiology of community-acquired pneumonia in the adult population of four municipalities in eastern Finland. Clin Infect Dis. 2001;15:1141–1154.
    1. Dowell SF, Anderson LJ, Gary HE., Jr Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infec Dis. 1996;174:456–462.
    1. Marx A, Gary HE, Jr, Marston BJ. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis. 1999;29:134–214.
    1. Peiris JSM, Lai ST, Poon LLM. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1312–1313.
    1. Arancifia F, Bauer TT, Ewig S. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa. Arch Intern Med. 2002;162:1849–1858.
    1. Park DR, Sherbin VL, Goodman MS. The aetiology of community-acquired pneumonia at an urban public hospital: influence of immunodeficiency virus infection and initial severity of illness. J Infect Dis. 2001;84:268–277.
    1. N Miyashita, H Fukano, Y Niki, T Matsushima, N Okimoto: Aetiology of community-acquired pneumonia requiring hospitalization in Japan. Chest 119; 1295–96.
    1. Ruiz-Gonzalez A, Falguera M, Nogues A. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown aetiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385–390.
    1. Luna CM, Famiglietti A, Absi R. Community-acquired pneumonia: aetiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 2000;118:1344–1354.
    1. Scott JA, Hall AJ, Muyodi C. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet. 2000;355:1225–1230.
    1. Lim WS, MacFarlane JT, Boswell TCJ. Study of community acquired pneumonia aetiology in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296–301.
    1. Wattanathum A, Chaoprasong C, Nunthapisud P, Chantaratchada S, Limpairojn N. Community-acquired pneumonia in southeast Asia. Chest. 2003;123:1512–1519.
    1. File TM, Jr, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am. 1998;12:569–592.
    1. Fine MJ, Stone RA, Singer DE. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159:970–980.
    1. Vergis EN, Akbas E, Yu VL. Legionella as a cause of severe pneumonia. Seminars in Respir Crit Care Med. 2000;21:295–304.
    1. Yu VL, Plouffe JF, Pastoris MC. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis. 2002;186:127–128.
    1. Bochud PY, Moser F, Erard P. Community-acquired pneumonia. A prospective outpatient study. Medicine. 2001;80:75–87.
    1. Falguera M, Sacristan O, Nogues A. Non-severe communityacquired pneumonia: correlation between cause and severity or comorbidity. Arch Int Med. 2001;161:1866–1887.
    1. Tan MJ, Tan JS, File TM., Jr Legionnaire’s disease with bacteremic coinfection. Clin Inf Dis. 2002;35:533–539.
    1. File TM, Jr, Plouffe JF, Jr, Breiman RF, Skelton SK. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis. 1999;29:426–428.
    1. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Resp Med. 1998;92:1137–1142.
    1. Kalin M, Ortvist A, Almela M. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Inf Dis. 2000;182:840–847.
    1. Mortensen EM, Coley CM, Singer DE. Arch Intern Med. 2002;162:1059–1064.
    1. Metlay JP, Kapoor WN, Fine MJ. Does this patient have communityacquired pneumonia? JAMA. 1997;278:1440–1445.
    1. Wipf JE, Lipsky BA, Hirschmann JV. Arch Intern Med. 1999;159:1082–1087.
    1. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27:358–363.
    1. Aronsky D, Dean NC. How should we make the admission decision in community-acquired pneumonia? Med Clin N America. 2001;85:1397–1411.
    1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Therapeutics. 1998;20:820–837.
    1. Coley CM, Yi-Hwei L, Medsger AR. Preference for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156:1565–1571.
    1. Fine MJ, Auble TE, Yealy DM. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250.
    1. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Inf Disease Clin N America. 1998;12:741–759.
    1. Atlas SJ, Benzer TI, Borowsky LH. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158:1350–1356.
    1. Marras TK, Gutierrez C, Chan CK. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest. 2000;118:1339–1343.
    1. Chan SS, Yuen EH, Kew J, Cheung WL, Cocks RA. Community-acquired pneumonia—implementation of a prediction rule to guide selection of patients for outpatient treatment. Europ J Emerg Med. 2001;8:279–286.
    1. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med. 2003;138:109–118.
    1. Lim WS, van der Eerden MM, Laing R. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382.
    1. Ewing S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia: assessment of severity criteria. Amer J Resp Crit Care Med. 1998;158:1102–1108.
    1. Angus DC, Marrie TJ, Obrosky DS. Severe community-acquired pneumonia. Use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717–723.
    1. Theerthakarai R, El-Halees W, Ismail M, Solis R, Khan MA. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest. 2001;119:181–184.
    1. Wunderink RG, Waterer GW. Appropriate Microbiological Testing in Community-Acquired Pneumonia. Chest. 2001;119:5–7.
    1. Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest. 2002;121:1486–1492.
    1. Korsgaard J, Rasmussen TR, Sommer T, Moller JK, Jensen JS, Kilian M. Intensified microbiological investigations in adult patients admitted to hospital with lower respiratory tract infections. Respir Med. 2002;96:344–351.
    1. Waterer GW, Jennings SG, Wunderink G. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest. 1999;116:1278–1281.
    1. Glerant JC, Hellmuth D, Schmit JL, Ducroix JP, Jounieaux V. Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission. Resp Medicine. 1999;93:208–212.
    1. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia. Chest. 2003;123:1142–1150.
    1. Meehan TP, Fine MJ, Krumholz HM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080–2084.
    1. Roson B, Carratala J, Verdaguer R. Prospective study of the usefulness of sputum gram stain in the initial approach to communitya-cquired pneumonia requiring hospitalization. Clin Infect Dis. 2000;31:869–874.
    1. Stout JE, Yu VL. Legionellosis. New Engl J Med. 1997;337:682–687.
    1. Waterer GW, Baselski VS, Wunderink RG. Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. Am J Med. 2001;110:41–48.
    1. Domínguez J, Galí N, Blanco S, Pedroso P, Prat C, Matas L, Ausina V. Detection of Streptococcus pneumoniae Antigen by a rapid immunochromatographic assay in urine samples. Chest. 2001;119:243–249.
    1. Burel E, Dufour P, Gauduchon V, Jarraud S, Etienne J. Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples. Eur J Clin Microbiol Infect Dis. 2001;20:840–841.
    1. Murdoch DR, Laing RT, Mills GD. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol. 2001;39:3495–3498.
    1. Gutierrez F, Rodriequez JC, Ayelo A. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis. 2003;36:286–292.
    1. Ramirez JA, Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Micro and Infect Dis. 1996;24:7–14.
    1. Tong CY, Donnelly C, Harvey G, Sillis M. Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci in respiratory samples. J Clin Path. 1999;52:257–263.
    1. Menendez R, Cordoba J, de La Cuadra P, Cremades MJ, Lopez-Hotagas JL, Salavert M, Gobernado M. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med. 1999;159:1868–1873.
    1. Scott JAG, Hall AJ. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest. 1999;116:1716–1732.
    1. Ishida T, Hashimoto T, Arita M, Osawa M, Tachibana H, Nishioka M, Ito I. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med. 2001;40:849–850.
    1. Doern GV, Heilmann KP, Huynh HK. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison or resistance rates since 1994–1995. Antimicrob Agents and Chemo. 2001;45:1721–1729.
    1. Whitney CG, Farley MM, Hadler J. Increasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–1924.
    1. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001;32(suppl 2):S81–S93.
    1. Felmingham D. Evolving Resistance Patterns in Community-acquired Respiratory Tract Pathogens: First Results from the PROTEKT Global Surveillance Study. J Infection. 2002;44(suppl A):3–10.
    1. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, and the Alexander project Group The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229–246.
    1. Richter SS, Heilmann KP, Coffman SL. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin Infect Diseases. 2002;34:330–339.
    1. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2002;2:404–415.
    1. Watanabe H, Sato S, Kawakami K. A comparative clinical study of pneumonia by penicillin-resistant and sensitive Streptococcus pneumoniae in a community hospital. Respirology. 2000;5:59–64.
    1. Moroney JF, Fiore AE, Harrison LH. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001;33:797–805.
    1. Klugman KP, Feldman C. Streptococcus pneumoniae respiratory tract infections. Curr Opin in Inf Dis. 2001;14:173–179.
    1. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin in Inf Dis. 2002;15:163–167.
    1. File TM., Jr Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;34(suppl):S17–S26.
    1. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β lactam antibiotics. Arch Intern Med. 2001;161:2538–2544.
    1. File TM, Jr, Jacobs MR, Michael D, Poole MD, Wynne B, the 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate. Int J Antimicrob Agents. 2002;20:235–247.
    1. Feikin DR, Schuchat A, Kolczak M. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health. 2000;90:223–229.
    1. Metlay JP, Hofmann J, Cetron MS. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:520–528.
    1. Campbell GD, Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1998;26:1188–1195.
    1. Leclercq R, Courvalin P. Resistance to macrolides and related 95 antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46:2727–2734.
    1. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother. 2002;49:433–436.
    1. Lynch JP, III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis. 2002;34(suppl 1):S27–S46.
    1. Siegel RE. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia. Are we looking in the wrong place? Chest. 1999;116:535–538.
    1. Rodvold KA, Gotfried MH, Danziger LH. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 1997;41(6):1399–1402.
    1. Hyde TB, Gay K, Stephens DS. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286:1857–1862.
    1. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis. 2000;31:613–615.
    1. Kelley MA, Weber DJ, Gilligan P. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 2000;31:1008–1011.
    1. Musher DM, Dowell ME, Shortridge VD. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:630–631.
    1. Lonks JR, Garau J, Gomez L. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant. Streptococcus pneumoniae Clin Infect Dis. 2002;35:556–559.
    1. Nishijima T, Saito Y, Aoki A. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics. J Antimicrob Chemother. 1999;43:637–643.
    1. Chen D, McGeer A, de Azavedo JC, Low DE. Canadian Bacterial Surveillance Network (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233–239.
    1. Ho PL, Yung RWH, Tsang DNC. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001;48:659–665.
    1. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother. 2002;49:173–176.
    1. Davidson R, Cavalcanti R, Brunton JL. Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance. New Engl J Med. 2002;346:747–750. L.
    1. Kays NB, Smith DW. Levofloxacin treatment failure in a patient with fluoroquinolone resistant Streptococcus pneumoniae pneumonia. Pharmacother. 2002;22:395–399.
    1. Ho PL, Tse WS, Tsang KW. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701–707.
    1. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother. 2001;48(suppl B):9–23.
    1. Stahl JE, Barza M, DesJardin J. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med. 1999;159:2576–2580.
    1. Gleason PP, Meehan TP, Fine JM. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562–2572.
    1. Dudas V, Hopefl A, Jacobs R. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000;34:446–452.
    1. Houck PM, MacLehose RF, Niederman MS. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119:1420–1426.
    1. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161:1837–1842.
    1. Martinez JA, Horcajada JP, Almeda M. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36:389–395.
    1. File TM, Jr, Mandell LA. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis. 2003;36:396–398.
    1. Hedlund J, Ortqvist A, Ahlquist T, Augustinsson A, Beckman H. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 2002;34:887–892.
    1. Kirk O, Glenthoj J, Dragsted UB. Penicillin as empirical therapy for patients hospitalized with community acquired pneumonia at a Danish hospital. Danish Medical Bulletin. 2001;48:84–88.
    1. Metersky ML. Community-acquired pneumonia: process of care studies. Curr Opin Inf Dis. 2002;15:169–174.
    1. Rhew DC, Tu GS, Ofman J. Early switch and early discharge strategies in patients with community-acquired pneumonia: a metaanalysis. Arch Intern Med. 2001;161:722–727.
    1. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic communityacquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161:848–850.
    1. Rhew DC, Hackner D, Henderson L. The clinical benefit of inhospital observation in ‘low-risk’ pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest. 1998;113:142–146.
    1. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu Al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162:1278–1284.
    1. Rhew DC. Quality indicators for the management of pneumonia in vulnerable elders. Annals Int Med. 2001;135:736–743.
    1. Bratzler DW, Houck PM, Nsa W. Initial processes of care and outcomes in elderly patients with pneumonia. Ann Emerg Med. 2001;38(suppl):S36.
    1. Dedier J, Singer DE, Chang Y, Moore M, Atlas S. Processes of care, illness severity, and outcomes in the management of communityacquired pneumonia at academic hospitals. Arch Intern Med. 2001;161:2099–2104.
    1. Benenson R, Magalske A, Cavanaugh S, Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Academic Emerg Med. 1999;6:1243–1248.
    1. Marrie TJ, Lau CY, Wheeler, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000;283:749–755.
    1. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001;110:541–547.
    1. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med. 2002;162:682–688.
    1. Dobbin CJ, Duggan CJ, Barnes DJ. The efficacy of an antibiotic protocol for community-acquired pneumonia. Med J Aust. 2001;174:333–337.
    1. Menendez R, Ferrando D, Valles JM. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 2002;122:612–617.
    1. Nathwani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis. 2001;32:728–741.
    1. Centers for Disease Control and Prevention General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Practice Physicians. MMWR Morb Mortal Week Rep. 2002;51 No RR-2.
    1. Gardner P, Pickering LK, Orenstein WA, Gershon AA, Nichol K. Guidelines for quality standards for immunization. Clin Infect Dis. 2002;35:503–511.
    1. Cornu C, Yzebe D, Leophonte P, Gaillt J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 2001;19:4780–4790.
    1. Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. The Lancet Inf Dis. 2001;1:85–91.
    1. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New Engl J Med. 2003;348:1737–1746.
Uncited reference
    1. Amsden GW. Pneumococcal macrolide resistance—myth or reality? J Antimicrob Chemother. 1999;44:1–6.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera